BIOLASE, Inc. (NASDAQ:BIOL) shares are surging after the company reported better-than-expected fourth-quarter FY23 EPS results.
Revenue of $13.49 million missed the consensus of $13.55 million. Gross profit stood at $3.52 million vs. $3.60 million a year ago.
EPS loss of $(1.76) was better than the consensus of $(2.56).
As of December 31, 2023, cash and cash equivalents stood at $6.57 million.
John Beaver, President and Chief Executive Officer, said, “The increased utilization …